References
- AJ Geib, K Babu, MB Ewald, and EW Boyer. Adverse effects in children after unintentional buprenorphine exposure. Pediatrics 2006; 118:1746–1751.
- R Ray, H Pal, R Kumar, P Maulick, and R Mangla. Post-marketing surveillance of buprenorphine. Pharmacoepidemiol Drug Saf 2004; 13:615–619.
- N Griessinger, R Sittl, and R Likar. Transdermal buprenorphine in clinical practice – a post-marketing surveillance study in 13.179 patients. Curr Med Res Opin 2005; 21:1147–1156.
- J Boyd, T Randell, H Luurila, and M Kuisma. Serious overdoses involving buprenorphine in Helsinki. Acta Anaesthesiol Scand 2003; 47:1031–1033.
- P Kintz. A new series of 13 buprenorphine-related deaths. Clin Biochem 2002; 35:513–516.
- A Tracqui, P Kintz, and B Ludes. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J Anal Toxicol 1998; 22:430–434.
- LE Edinboro, A Poklis, D Trautman, S Lowry, R Backer, and CM Harvey. Fatal fentanyl intoxication following excessive transdermal application. J Forensic Sci 1997; 42:741–743.
- S Tank, K Stork, W Skibba, S Zittel, H Andresen, AE Goetz, H Beck. Accidental intoxication with unlabeled, generic transdermal fentanyl patches caused by insufficient instruction. (in German), Anaesthesist 2007; (Epub ahead of print – Accessed August 2nd, 2007 at PubMed website http://www.ncbi.nlm.nih.gov/).
- Characterization of Medical Product – Transtec 35 microg/h, Transtec 52.5 microg/h and Transtec 70 microg/h (Buprenorphinum). (In Polish), The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products Home Page, Poland, (Accessed August 2nd, 2007 at http://www.urpl.gov.pl/rejestr/Transtec.pdf).
- KA Sporer. Buprenorphine: a primer for emergency physicians. Ann Emerg Med 2004; 43:580–584.